Update on genetic risk factors for systemic lupus erythematosus and rheumatoid arthritis

2000 ◽  
Vol 12 (2) ◽  
pp. 85-90 ◽  
Author(s):  
Lindsey A. Criswell ◽  
Christopher I. Amos
2012 ◽  
Vol 39 (8) ◽  
pp. 1603-1610 ◽  
Author(s):  
RACHEL KAISER ◽  
YONGHONG LI ◽  
MONICA CHANG ◽  
JOSEPH CATANESE ◽  
ANN B. BEGOVICH ◽  
...  

Objective.Thrombosis is a serious complication of systemic lupus erythematosus (SLE). We investigated whether genetic variants implicated in thrombosis pathways are associated with thrombosis among 2 ethnically diverse SLE cohorts.Methods.Our discovery cohort consisted of 1698 patients with SLE enrolled in the University of California, San Francisco, Lupus Genetics Project and our replication cohort included 1361 patients with SLE enrolled in the PROFILE cohort. Patients fulfilled American College of Rheumatology SLE criteria, and data relevant to thrombosis were available. Thirty-three single nucleotide polymorphisms (SNP) previously shown to be associated with risk of deep venous thrombosis in the general population or implicated in thrombosis pathways were genotyped and tested for association with thrombosis in bivariate allelic analyses. SNP with p < 0.1 in the bivariate analyses were further tested in multivariable logistic regression models adjusted for age, sex, disease duration, antiphospholipid antibody status, smoking, nephritis, and medications.Results.In the discovery cohort, 23% of patients with SLE experienced a thrombotic event. SNP in the following genes demonstrated association with thrombosis risk overall in the discovery or replication cohorts and were assessed using metaanalytic methods: factor V Leiden (FVL) rs6025 (OR 1.85, p = 0.02) and methylenetetrahydrofolate reductase (MTHFR) rs1801133 (OR 0.75, p = 0.04) in whites, and fibrinogen gamma (FGG) rs2066865 (OR 1.91, p = 0.01) in Hispanic Americans. SNP in these genes showed association with venous thrombosis risk in whites: MTHFR rs1801131 (OR 1.51, p = 0.01), MTHFR rs1801133 (OR 0.70, p = 0.04), FVL rs6025 (OR 2.69, p = 0.002), and FGG rs2066865 (OR 1.49, p = 0.02) in whites. A SNP in FGG rs2066865 (OR 2.19, p = 0.003) demonstrated association with arterial thrombosis risk in Hispanics.Conclusion.Our results implicate specific genetic risk factors for thrombosis in patients with SLE and suggest that genetic risk for thrombosis differs across ethnic groups.


2003 ◽  
Vol 25 (2) ◽  
pp. 97-102 ◽  
Author(s):  
Tae-Young Kang ◽  
Hye-Soon Lee ◽  
Tae-Hwan Kim ◽  
Jae-Bum Jun ◽  
Dae-Hyun Yoo

2005 ◽  
Vol 25 (1) ◽  
pp. 77-84 ◽  
Author(s):  
Wannaporn Ittiprasert ◽  
Surasak Kantachuvesiri ◽  
Kanok Pavasuthipaisit ◽  
Orawan Verasertniyom ◽  
Lulin Chaomthum ◽  
...  

2007 ◽  
Vol 56 (8) ◽  
pp. 2679-2686 ◽  
Author(s):  
Brent W. Kinder ◽  
Michelle M. Freemer ◽  
Talmadge E. King ◽  
Raymond F. Lum ◽  
Joanne Nititham ◽  
...  

2011 ◽  
Vol 33 (1) ◽  
pp. 35-43 ◽  
Author(s):  
Hanan El Saadany ◽  
Mervat El-Sergany ◽  
Elham Kasem ◽  
Manal M. El-Batch ◽  
Soha S. Zakaria ◽  
...  

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1049.3-1050
Author(s):  
E. Gerasimova ◽  
T. Popkova ◽  
T. Kirichenko ◽  
А . Markin ◽  
Y. Markina ◽  
...  

Background:The study of the ability of monocytes to activate associated with the clinical activity of immunological markers of inflammation in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) will provide important and fundamentally new information on the involvement of these cells in the development of autoimmune rheumatic diseases (ARDs).Objectives:To study macrophage activation in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients (pts).Methods:A total of 21 active ARDs pts (11 RA, 10 SLE) were enrolled in the study (median age was 55[44; 63] years; disease duration was 8 [2; 14] months). There are 11 pts with early RA (disease duration was ≤12 months), moderate to high activity (DAS28 was 6.1[4.9;6.7]; SDAI was 25(22;31); ACCP was positive in 73% and RF in 87% cases) and 10 pts with active SLE (SLADAI-2K was 7 [6;8]) in the study. All early RA pts and 4 SLE pts were not treated with glucocorticoids and disease-modifying antirheumatic drugs. Six SLE pts received low-dose glucocorticoids and hydroxychloroquine.All pts were assessed for macrophage activation and laboratory data: ESR, RF, ACCP, CRP, ANA, anti-dsDNA. Isolation of monocytes was carried out according to the standard procedure for obtaining a leukocyte fraction in a Ficoll gradient and subsequent selection of CD14 + cells using magnetic separation. After isolation, the cells were cultured in X-Vivo medium. To assess the degree of monocyte activation, cells were stimulated by the addition of LPS. The value of monocyte activation was expressed as a ratio of the level of secretion of proinflammatory cytokines by monocytes cultured with and without LPS addition. Secretion levels were determined by ELISA. The belonging of the isolated cells to CD14 + monocytes was additionally confirmed by flow cytometry.Results:Macrophage activation was 2.6 (2.0;5.4) and 4.8 (2.8;7.3) in RA and SLE pts, respectively (p>0.05). In RA and SLE pts macrophage activation was independent of age, sex, body mass index, traditional risk factors (arterial hypertension, overweight, smoking, family history of cardiovascular diseases), RA activity scores (DAS28, SDAI), and SLADAI-2K. No association was found between macrophage activation and levels of ESR, RF, ACCP, CRP, ANA, and anti-dsDNA.Conclusion:No differences in macrophage activation were found in RA and SLE pts. Macrophage activation was independent of age, sex, traditional risk factors, and ARD-related parameters. A study on a larger number of pts will clarify the link between macrophage activation and autoimmune disorders.This work was supported by the Russian Science Foundation (Grant № 21-15-00225).Disclosure of Interests:None declared


2009 ◽  
Vol 70 (4) ◽  
pp. 251-256 ◽  
Author(s):  
Silvia Jiménez-Morales ◽  
Rafael Velázquez-Cruz ◽  
Julián Ramírez-Bello ◽  
Edmundo Bonilla-González ◽  
Sandra Romero-Hidalgo ◽  
...  

2020 ◽  
Vol 2 ◽  
pp. 8 ◽  
Author(s):  
Weilin Song ◽  
Justin C. Muste ◽  
Tyler E. Greenlee ◽  
Rishi P. Singh

Chloroquine and hydroxychloroquine have been used for decades as antimalarials and also as immunomodulating therapies for rheumatic diseases such as systemic lupus erythematosus and rheumatoid arthritis. They also have antiviral properties and are currently used empirically for the treatment of coronavirus disease 2019 (COVID-19). Retinal toxicity is a potential complication of these medications. Current ophthalmic screening and dosing recommendations aim to decrease the risk of developing retinopathy or prevent its progression. Baseline fundus examination is not currently recommended before initiating chloroquine or hydroxychloroquine for COVID-19 due to presumed very low risk of retinal toxicity. However, doses of the drugs used for the treatment of COVID-19 exceed the recommended doses, and patients often have additional risk factors. Research in the future is warranted to confirm the risk and incidence of toxicity with this novel use.


Sign in / Sign up

Export Citation Format

Share Document